The pathology of soft tissue sarcomas.
Immunohistochemistry
Molecular genetics
Soft tissue sarcoma
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
16
02
2018
accepted:
29
03
2018
pubmed:
28
6
2018
medline:
27
4
2019
entrez:
28
6
2018
Statut:
ppublish
Résumé
Soft tissue sarcomas represent a heterogeneous group of rare malignancies exhibiting mesenchymal differentiation with an overall incidence of around 5/100,000/year. Rarity and morphologic heterogeneity significantly affect diagnostic accuracy; therefore, expertise can be achieved only through access to large number of cases. Soft tissue sarcomas are currently classified on the basis of the 2013 WHO classification of soft tissue tumors that integrate conventional morphology with immunohistochemistry and molecular genetics. The morphologic diagnosis of sarcoma relies on the evaluation as well as the integration of four main features: the shape of the neoplastic cells; the pattern of growth; the quality of the background; the architecture of the vascular network. Immunohistochemical characterization plays a key role in the diagnostic workup of soft tissue sarcomas. The majority of classic differentiation markers tend to show good sensitivity, however, associated with rather limited specificity, making interpretation in context with morphology mandatory. Molecular genetics is increasingly used for diagnostic purposes to distinguish specific subtypes of sarcomas, to support diagnosis in non-canonical clinical presentations and also to distinguish true sarcomas from benign mimickers. With many exceptions, histologic typing does not provide sufficient information for predicting the clinical course of the disease and, therefore, grading systems based on histological parameters were introduced to provide a more accurate estimation of the degree of malignancy of tumors. The three-tiered system devised by the French Federation of Cancer Centers Sarcoma Group (FNCLCC) systems is widely adopted; however, several limitations exist that have led to the development of prognostic nomograms that incorporate the specific histotype as one of the relevant parameters.
Identifiants
pubmed: 29948548
doi: 10.1007/s11547-018-0882-7
pii: 10.1007/s11547-018-0882-7
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-281Références
J Pathol. 2014 Apr;232(5):534-40
pubmed: 24374978
Clin Cancer Res. 2016 Feb 15;22(4):837-46
pubmed: 26261104
N Engl J Med. 2010 Oct 28;363(18):1727-33
pubmed: 20979472
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
J Clin Oncol. 1997 Jan;15(1):350-62
pubmed: 8996162
Surg Pathol Clin. 2017 Sep;10(3):587-620
pubmed: 28797504
Semin Diagn Pathol. 2013 Nov;30(4):375-81
pubmed: 24342291
J Pathol. 2016 Mar;238(4):543-9
pubmed: 26606880
Expert Rev Anticancer Ther. 2015;15(12):1473-88
pubmed: 26536249
Lab Invest. 2005 Mar;85(3):408-15
pubmed: 15640831
Am J Surg Pathol. 2013 Aug;37(8):1259-68
pubmed: 23774173
Lancet Oncol. 2016 Sep;17(9):1261-71
pubmed: 27498913
Nat Med. 2010 Jul;16(7):781-7
pubmed: 20581836
Histopathology. 2011 Aug;59(2):336-40
pubmed: 21884214
Mod Pathol. 2014 Jan;27 Suppl 1:S47-63
pubmed: 24384853
Nat Genet. 2010 Aug;42(8):715-21
pubmed: 20601955
Ann Oncol. 2012 Sep;23(9):2442-9
pubmed: 22331640
N Engl J Med. 2015 Jul 30;373(5):428-37
pubmed: 26222558
Cancer. 2001 May 15;91(10):1914-26
pubmed: 11346874
Am J Surg Pathol. 2007 Oct;31(10):1476-89
pubmed: 17895748
Histopathology. 2014 Jan;64(1):101-18
pubmed: 24111893
J Clin Oncol. 2018 Jan 10;36(2):101-110
pubmed: 29220288